Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel
非格司亭剂量递增并不能提高疗效：CALGB 9141 研究的临床耐受性和长期随访结果显示，采用剂量强化的多柔比星联合环磷酰胺序贯紫杉醇方案治疗淋巴结阳性乳腺癌患者的辅助化疗方案，疗效并不理想。
期刊:Cancer Treatment Reviews
影响因子:10.5
doi:10.1016/j.ctrv.2007.11.004
Liu, Minetta C; Demetri, George D; Berry, Donald A; Norton, Larry; Broadwater, Gloria; Robert, Nicholas J; Duggan, David; Hayes, Daniel F; Henderson, I Craig; Lyss, Alan; Hopkins, Judith; Kaufman, Peter A; Marcom, P Kelly; Younger, Jerry; Lin, Nancy; Tkaczuk, Katherine; Winer, Eric P; Hudis, Clifford A
